GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

Pornpak Khunatorn/iStock via Getty Images

• The shares of clinical-stage biotech GeoVax Labs (NASDAQ:GOVX) added ~16% in the morning hours Thursday after the company announced a peer-reviewed publication of an animal efficacy study on the company’s experimental vaccine for Sudan ebolavirus (SUDV).
• According to data posted on the Nature Partner Journals (NPJ) Vaccines, a single dosed of the vaccine, MVA-VLP-SUDV, was found to generate 100% protection in the study involving guinea pigs.
• A second vaccine dose further bolstered the vaccine responses of the animals, the company said, adding that all animals which received either one or two doses of MVA-VLP-SUDV developed protection against death and symptoms following a lethal dose of SUDV.
• “The resulting immune responses are broadly functional, involving both the antibody and T-cell effector function, resulting in optimal levels of efficacy, even with a single dose,” Chief Executive of GeoVax (GOVX) Mark J. Newman explained.
• The company is close to completing its ongoing study for the candidate involving nonhuman primates.
• Benefitting from the recent monkeypox outbreak, GeoVax (GOVX) shares have climbed ~94% over the past 30 days, as shown in this graph.